Health systems are broken for many living in low- and middle -income countries, where people suffer and die not because an intervention doesn’t exist, but because they don’t have access to it. Scott Boyer saw this first-hand during his 25 years in Big Pharma, where the far-right column on sales charts showed a tiny bar representing “ROW” – the 170+ countries in the “Rest of World” where no profitable market exists. He left to form a new model – a hybrid social enterprise that combines the best of for-profit and non-profit structures to generate capital and deploy it globally. ROW Global Health and OWP Pharmaceuticals form a “tandem hybrid” social enterprise that has already delivered over $22M in medication grants through 70 partnerships in 38 countries – and they’re just getting started. This panel will discuss the pros and cons of for-profit, non-profit, and hybrid models built for global impact, and how innovative partnerships and new ways of thinking can uproot systemic injustices.
Flipping the Script: How a Hybrid Social Enterprise in Pharma is Mobilizing Medication for the “Rest of World”
Track
Transforming Health Systems
Format
Panel (3 speakers)
Speakers
- NameScott Boyer
- TitleFounder, CEO
- OrganizationOWP Pharmaceuticals
- NameArchana Patel
- TitlePediatric Neurologist, Boston Children’s Hospital; Assistant Professor of Neurology, Harvard Medical School
- OrganizationBoston Children's Hospital / Harvard Medical School
- NameJeremy Gudauskas
- TitleDirector of Philanthropy
- OrganizationROW Global Health
Description
Health systems are broken for many living in low- and middle -income countries, where people suffer and die not because an intervention doesn’t exist, but because they don’t have access to it. Scott Boyer saw this first-hand during his 25 years in Big Pharma, where the far-right column on sales charts showed a tiny bar representing “ROW” – the 170+ countries in the “Rest of World” where no profitable market exists. He left to form a new model – a hybrid social enterprise that combines the best of for-profit and non-profit structures to generate capital and deploy it globally. ROW Global Health and OWP Pharmaceuticals form a “tandem hybrid” social enterprise that has already delivered over $22M in medication grants through 70 partnerships in 38 countries – and they’re just getting started. This panel will discuss the pros and cons of for-profit, non-profit, and hybrid models built for global impact, and how innovative partnerships and new ways of thinking can uproot systemic injustices.
